Replimune (REPL) Asset Writedowns and Impairment (2022 - 2023)
Replimune (REPL) reported Asset Writedowns and Impairment of $273000.0 for Q4 2023, up 16.17% on a YoY basis from $235000.0 in Q4 2022, and up 6.64% sequentially from $256000.0 in Q3 2023.
Replimune (REPL) Asset Writedowns and Impairment (2022 - 2023) Analysis & Trends
Replimune (REPL) has 2 years of Asset Writedowns and Impairment data on file, last reported at $273000.0 in Q4 2023.
- For the quarter ending Q4 2023, Asset Writedowns and Impairment rose 16.17% year-over-year to $273000.0; the trailing twelve-month figure through Dec 2023 stood at $1.0 million (changed N/A YoY), and the FY2026 full-year result was $188000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $273000.0 in Q4 2023, from $256000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $273000.0 in Q4 2023 to a low of $235000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 256,000.00 |
| Sep 30, 2023 | 256,000.00 |
| Jun 30, 2023 | 257,000.00 |
| Jun 30, 2023 | 257,000.00 |
| Dec 31, 2022 | 235,000.00 |
| Dec 31, 2022 | 235,000.00 |